Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)

NCT01852604 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

143

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C Virus

Interventions

DRUG: Samatasvir
DRUG: Simeprevir
DRUG: Ribavirin (RBV)
DRUG: TMC647055
DRUG: Ritonavir (RTV)
BIOLOGICAL: Pegylated interferon (Peg-IFN)
OTHER: Samatasvir matching placebo

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]